SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
呦吼。。。
Lv6
12
2364 积分
2021-10-12 加入
最近求助
最近应助
互助留言
Retrospective analysis of immune checkpoint inhibitor-associated myocarditis from 12 cancer centers in China
3天前
已关闭
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
4天前
已完结
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
5天前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
5天前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
5天前
已完结
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
5天前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
5天前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
5天前
已完结
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
14天前
已完结
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance
14天前
已完结
没有进行任何应助
感谢
5天前
感谢
5天前
感谢
5天前
感谢,点赞
25天前
感谢
1个月前
感谢
1个月前
感谢
1个月前
已找到【积分已退回】
1个月前
感谢
2个月前
已下载【积分已退回】
2个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论